Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

The Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor Beds.

Rutkowski MR, Svoronos N, Perales-Puchalt A, Conejo-Garcia JR.

Adv Cancer Res. 2015;128:235-62. doi: 10.1016/bs.acr.2015.04.011. Epub 2015 May 21. Review.

2.

Multiparametric MRI for recurrent prostate cancer post radical prostatectomy and postradiation therapy.

Barchetti F, Panebianco V.

Biomed Res Int. 2014;2014:316272. doi: 10.1155/2014/316272. Epub 2014 May 25. Review.

3.

Advanced imaging for the early diagnosis of local recurrence prostate cancer after radical prostatectomy.

Panebianco V, Barchetti F, Musio D, De Felice F, Proietti C, Indino EL, Megna V, Schillaci O, Catalano C, Tombolini V.

Biomed Res Int. 2014;2014:827265. doi: 10.1155/2014/827265. Epub 2014 Mar 13. Review.

4.

Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.

Gu L, Talati P, Vogiatzi P, Romero-Weaver AL, Abdulghani J, Liao Z, Leiby B, Hoang DT, Mirtti T, Alanen K, Zinda M, Huszar D, Nevalainen MT.

Mol Cancer Ther. 2014 May;13(5):1246-58. doi: 10.1158/1535-7163.MCT-13-0605. Epub 2014 Feb 27.

5.

Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score.

Akaza H, Hinotsu S, Usami M, Ogawa O, Kitamura T, Suzuki K, Tsukamoto T, Naito S, Namiki M, Hirao Y, Murai M.

Prostate Int. 2013;1(2):81-8. doi: 10.12954/PI.12016. Epub 2013 Jun 30.

6.

Pituitary apoplexy induced by Gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case.

Huang TY, Lin JP, Lieu AS, Chen YT, Chen HS, Jang MY, Shen JT, Wu WJ, Huang SP, Juan YS.

World J Surg Oncol. 2013 Oct 2;11:254. doi: 10.1186/1477-7819-11-254.

7.

STAT5A/B gene locus undergoes amplification during human prostate cancer progression.

Haddad BR, Gu L, Mirtti T, Dagvadorj A, Vogiatzi P, Hoang DT, Bajaj R, Leiby B, Ellsworth E, Blackmon S, Ruiz C, Curtis M, Fortina P, Ertel A, Liu C, Rui H, Visakorpi T, Bubendorf L, Lallas CD, Trabulsi EJ, McCue P, Gomella L, Nevalainen MT.

Am J Pathol. 2013 Jun;182(6):2264-75. doi: 10.1016/j.ajpath.2013.02.044. Epub 2013 May 7.

8.

An economic analysis of conservative management versus active treatment for men with localized prostate cancer.

Perlroth DJ, Bhattacharya J, Goldman DP, Garber AM.

J Natl Cancer Inst Monogr. 2012 Dec;2012(45):250-7. doi: 10.1093/jncimonographs/lgs037.

9.

Transdermal estradiol in castrate and chemotherapy resistant prostate cancer.

Stein M, Goodin S, Doyle-Lindrud S, Silberberg J, Kane M, Metzger D, Eddy S, Shih W, DiPaola RS.

Med Sci Monit. 2012 Apr;18(4):CR260-4.

10.

Use of androgen deprivation therapy in prostate cancer: indications and prevalence.

Connolly RM, Carducci MA, Antonarakis ES.

Asian J Androl. 2012 Mar;14(2):177-86. doi: 10.1038/aja.2011.103. Epub 2012 Jan 9. Review.

11.

Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models.

Gravina GL, Marampon F, Piccolella M, Motta M, Ventura L, Pomante R, Popov VM, Zani BM, Pestell RG, Tombolini V, Jannini EA, Festuccia C.

Endocrinology. 2011 Dec;152(12):4550-61. doi: 10.1210/en.2011-1056. Epub 2011 Oct 11.

12.

A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma.

Lin YH, Chen CL, Hou CP, Chang PL, Tsui KH.

Acta Pharmacol Sin. 2011 Apr;32(4):537-42. doi: 10.1038/aps.2010.236. Epub 2011 Mar 14.

13.

Development of a real-time clinical decision support system upon the Web MVC-based architecture for prostate cancer treatment.

Lin HC, Wu HC, Chang CH, Li TC, Liang WM, Wang JY.

BMC Med Inform Decis Mak. 2011 Mar 8;11:16. doi: 10.1186/1472-6947-11-16.

14.

Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.

Gillessen S, Templeton A, Marra G, Kuo YF, Valtorta E, Shahinian VB.

J Natl Cancer Inst. 2010 Dec 1;102(23):1760-70. doi: 10.1093/jnci/djq419. Epub 2010 Nov 10.

15.

Sex hormones and colorectal cancer: what have we learned so far?

Lin JH, Giovannucci E.

J Natl Cancer Inst. 2010 Dec 1;102(23):1746-7. doi: 10.1093/jnci/djq444. Epub 2010 Nov 10. No abstract available.

16.

Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists.

Loblaw DA, Pickles T, Cheung PC, Lukka H, Faria S, Klotz L.

Can Urol Assoc J. 2009 Dec;3(6):460-4.

17.

Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.

Knudsen KE, Scher HI.

Clin Cancer Res. 2009 Aug 1;15(15):4792-8. doi: 10.1158/1078-0432.CCR-08-2660. Epub 2009 Jul 28. Review.

18.

Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study.

Dale W, Hemmerich J, Bylow K, Mohile S, Mullaney M, Stadler WM.

J Clin Oncol. 2009 Apr 1;27(10):1557-63. doi: 10.1200/JCO.2008.18.5850. Epub 2009 Mar 2.

19.

Management of complications of androgen deprivation therapy in the older man.

Mohile SG, Mustian K, Bylow K, Hall W, Dale W.

Crit Rev Oncol Hematol. 2009 Jun;70(3):235-55. doi: 10.1016/j.critrevonc.2008.09.004. Epub 2008 Oct 25. Review.

20.

AR, the cell cycle, and prostate cancer.

Balk SP, Knudsen KE.

Nucl Recept Signal. 2008 Feb 1;6:e001. doi: 10.1621/nrs.06001. Review.

Items per page

Supplemental Content

Write to the Help Desk